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The goal of a non-inferiority (NI) trial is to deter-
mine whether or not a new treatment is no worse
than an existing treatment on some outcome of
interest. Analysis based on the intention-to-treat
(ITT) principle is anti-conservative in this instance,
so current guidelines recommend analysing on a
per-protocol (PP) population in addition. However,
PP analysis relies on the often implausible assumption
of no unmeasured confounders. Randomisation-based
efficacy estimators (RBEEs) allow for treatment non-
adherence whilst maintaining a comparison of rando-
mised groups. Fischer et al. have developed an
approach for estimating RBEEs in randomised trials
with two active treatments, a common feature of NI
trials.
The aim of this talk is to demonstrate the use of these
methods, proposing their use as a primary analysis in NI
trials.
By treating randomisation as an instrument, estimates
of treatment efficacy can be derived that maintain a
comparison of randomised groups and are therefore not
prone to selection bias. These models can be fitted
using instrumental variables regression using standard
statistical software. In addition, the method relies on
identifying baseline variables that differentially predict
adherence by treatment group, while remaining inde-
pendent of outcome.
Two examples of real NI trials are presented; where it is
and is not possible to derive distinct causal estimators.
The process of identifying predictors will be described,
and the estimates of treatment efficacy will be presented
alongside the ITT and PP analyses. The process of
estimating treatment efficacy when distinct causal para-
meters cannot be identified will also be demonstrated.
This work will highlight the value of this approach when
estimating treatment effects in NI trials. It will also high-
light the importance of collecting baseline data that may
be associated with adherence differently in the different
treatment groups, and also the how adherence to study
treatment is collected and defined.
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